Curis Q1 2023 Earnings Report
Key Takeaways
Curis reported a net loss of $11.6 million, or $0.12 per share, for the first quarter of 2023. Revenues were $2.3 million, and the company's cash and investments totaled $71.8 million. The company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3.
Curis enrolled additional patients requested by FDA ahead of schedule in the first quarter for the TakeAim leukemia study.
The company is on track to collect data from these patients in the second quarter and discuss these data with the FDA in the third quarter of this year.
Jonathan Zung, Ph.D. was appointed as Chief Development Officer.
Curis expects its existing cash, cash equivalents and investments should enable it to maintain its planned operations into 2025.
Curis
Curis
Forward Guidance
Curis expects to discuss data with the FDA in the third quarter of 2023 to determine the recommended Phase 2 dose and resolution of the partial clinical hold on emavusertib development in leukemia.